Saturday, 26 November 2011

Fentul




Fentul may be available in the countries listed below.


Ingredient matches for Fentul



Ifosfamide

Ifosfamide is reported as an ingredient of Fentul in the following countries:


  • Argentina

International Drug Name Search

Posted by at No comments:
Labels:

Friday, 25 November 2011

Fluvoxamin Stada




Fluvoxamin Stada may be available in the countries listed below.


Ingredient matches for Fluvoxamin Stada



Fluvoxamine

Fluvoxamine maleate (a derivative of Fluvoxamine) is reported as an ingredient of Fluvoxamin Stada in the following countries:


  • Germany

International Drug Name Search

Posted by at No comments:
Labels:

Thursday, 24 November 2011

Inspra


Inspra is a brand name of eplerenone, approved by the FDA in the following formulation(s):


INSPRA (eplerenone - tablet; oral)



  • Manufacturer: GD SEARLE LLC

    Approval date: September 27, 2002

    Strength(s): 25MG [AB], 50MG [RLD][AB]

Has a generic version of Inspra been approved?


A generic version of Inspra has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Inspra and have been approved by the FDA:


eplerenone tablet; oral



  • Manufacturer: APOTEX

    Approval date: July 30, 2008

    Strength(s): 25MG [AB], 50MG [AB]


  • Manufacturer: SANDOZ

    Approval date: August 1, 2008

    Strength(s): 25MG [AB], 50MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Inspra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Immediate release eplerenone compositions
    Patent 6,410,054
    Issued: June 25, 2002
    Inventor(s): Shilpa S.; Thosar & Rajeev D.; Gokhale & Dwain S.; Tolbert
    Assignee(s): G. D. Searle & Co.
    The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.
    Patent expiration dates:

    • December 8, 2019
      ✓ 
      Patent use: TREATMENT OF HYPERTENSION


    • December 8, 2019
      ✓ 
      Patent use: TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE


    • June 8, 2020
      ✓ 
      Pediatric exclusivity




  • Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
    Patent 6,410,524
    Issued: June 25, 2002
    Inventor(s): Alfonzo T.; Perez & Debra J.; Asner & Richard J.; LaChapelle & John C.; Alexander & Barbara; Roniker
    Assignee(s): G. D. Searle & Co.
    Combinations of an ACE inhibitor, an aldosterone antagonist, and a loop diuretic are described for use in treatment of circulatory disorders. Of particular interest are therapies using captopril, enalapril or lisinopril co-administered with spironolactone. This co-therapy would be particularly useful to reduce the death rate or the number of non-fatal hospitalizations or prevent the progression of congestive heart failure in patients with cardiovascular disease.
    Patent expiration dates:

    • November 5, 2019
      ✓ 
      Patent use: USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION


    • May 5, 2020
      ✓ 
      Pediatric exclusivity




  • Eplerenone compositions having improved bioavailability
    Patent 6,495,165
    Issued: December 17, 2002
    Inventor(s): Shilpa S.; Thosar & Rajeev D.; Gokhale & Dwain S.; Tolbert
    Assignee(s): G.D. Searle & Co.
    The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.
    Patent expiration dates:

    • December 8, 2019
      ✓ 
      Patent use: TREATMENT OF HYPERTENSION


    • December 8, 2019
      ✓ 
      Patent use: TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE


    • June 8, 2020
      ✓ 
      Pediatric exclusivity




  • Immediate release eplerenone compositions
    Patent 6,534,093
    Issued: March 18, 2003
    Inventor(s): Shilpa S.; Thosar & Rajeev D.; Gokhale & Dwain S.; Tolbert
    Assignee(s): G.D. Searle & Co.
    The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.
    Patent expiration dates:

    • December 8, 2019
      ✓ 
      Patent use: TREATMENT OF HYPERTENSION


    • December 8, 2019
      ✓ 
      Patent use: TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE


    • June 8, 2020
      ✓ 
      Pediatric exclusivity




  • Immediate release eplerenone compositions
    Patent 6,558,707
    Issued: May 6, 2003
    Inventor(s): Shilpa S.; Thosar & Rajeev D.; Gokhale & Dwain S.; Tolbert
    Assignee(s): G. D. Searle & Co.
    The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.
    Patent expiration dates:

    • December 8, 2019
      ✓ 
      Patent use: TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
      ✓ 
      Drug product


    • June 8, 2020
      ✓ 
      Pediatric exclusivity




  • Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor
    Patent 6,747,020
    Issued: June 8, 2004
    Inventor(s): Alfonzo T.; Perez & Debra J.; Asner & Richard J.; LaChapelle & John C.; Alexander & Barbara; Roniker
    Assignee(s): Pharmacia Corporation
    Methods of using eplerenone, an angiotensin converting enzyme inhibitor and optionally a diuretic are described for treatment of heart failure and hypertension.
    Patent expiration dates:

    • November 5, 2019
      ✓ 
      Patent use: USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION


    • May 5, 2020
      ✓ 
      Pediatric exclusivity




  • Immediate release eplerenone compositions
    Patent 6,863,902
    Issued: March 8, 2005
    Inventor(s): Thosar; Shilpa S. & Gokhale; Rajeev D. & Tolbert; Dwain S.
    Assignee(s): G. D. Searle & Co.
    The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.
    Patent expiration dates:

    • April 10, 2020
      ✓ 
      Patent use: TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
      ✓ 
      Drug product


    • October 10, 2020
      ✓ 
      Pediatric exclusivity




  • Micronized eplerenone compositions
    Patent 7,157,101
    Issued: January 2, 2007
    Inventor(s): Thosar; Shilpa S. & Gokhale; Rajeev D. & Tolbert; Dwain S.
    Assignee(s): G.D. Searle, LLC
    The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and one or more carrier materials.
    Patent expiration dates:

    • December 8, 2019
      ✓ 
      Patent use: TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
      ✓ 
      Drug product


    • June 8, 2020
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • January 31, 2011 - INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS

    • July 31, 2011 - PEDIATRIC EXCLUSIVITY

See also...

  • Inspra Consumer Information (Wolters Kluwer)
  • Inspra Consumer Information (Cerner Multum)
  • Inspra Advanced Consumer Information (Micromedex)
  • Inspra AHFS DI Monographs (ASHP)
  • Eplerenone Consumer Information (Wolters Kluwer)
  • Eplerenone Consumer Information (Cerner Multum)
  • Eplerenone Advanced Consumer Information (Micromedex)
  • Eplerenone AHFS DI Monographs (ASHP)
Posted by at No comments:
Labels:

Wednesday, 23 November 2011

Fénofibrate Zydus




Fénofibrate Zydus may be available in the countries listed below.


Ingredient matches for Fénofibrate Zydus



Fenofibrate

Fenofibrate is reported as an ingredient of Fénofibrate Zydus in the following countries:


  • France

International Drug Name Search

Posted by at No comments:
Labels:

Monday, 21 November 2011

Esomed




Esomed may be available in the countries listed below.


Ingredient matches for Esomed



Hydroquinone

Hydroquinone is reported as an ingredient of Esomed in the following countries:


  • Israel

International Drug Name Search

Posted by at No comments:
Labels:

Saturday, 19 November 2011

Estriol-Ovulum Jenapharm




Estriol-Ovulum Jenapharm may be available in the countries listed below.


Ingredient matches for Estriol-Ovulum Jenapharm



Estriol

Estriol is reported as an ingredient of Estriol-Ovulum Jenapharm in the following countries:


  • Germany

International Drug Name Search

Posted by at No comments:
Labels:

Wednesday, 16 November 2011

Idedex




Idedex may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Idedex



Glycerol

Glycerol is reported as an ingredient of Idedex in the following countries:


  • Australia

Povidone Iodine

Povidone-Iodine is reported as an ingredient of Idedex in the following countries:


  • Australia

International Drug Name Search

Posted by at No comments:
Labels:

Tuesday, 15 November 2011

Doctor




Doctor may be available in the countries listed below.


Ingredient matches for Doctor



Miconazole

Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Doctor in the following countries:


  • Argentina

International Drug Name Search

Posted by at No comments:
Labels:

Friday, 11 November 2011

Aluminium Hydroxide




In some countries, this medicine may only be approved for veterinary use.

Scheme

Ph. Int.

ATC (Anatomical Therapeutic Chemical Classification)

A02AB01

CAS registry number (Chemical Abstracts Service)

0021645-51-2

Chemical Formula

Al-(OH)3

Molecular Weight

78

Therapeutic Categories

Pharmaceutic aid

Antacid

Chemical Names

Aluminium Hydroxide (Ph. Int.)

Aluminium trihydrate

Hydrated alumina

Foreign Names

  • Aluminii hydroxidum (Latin)
  • Aluminium hydroxid (German)

Generic Names

  • UNII-5QB0T2IUN0 (IS)
  • Aluminium Hydroxide (PH: Ph. Int. 4)
  • Aluminium Hydroxide Dried (PH: BP 2010)
  • Aluminum Hydroxide Gel (PH: USP 32)
  • Dried Aluminum Hydroxide Gel (PH: USP 32)
  • Dried Aluminum Hydroxide Gel Capsules (PH: USP 32)
  • Dried Aluminum Hydroxide Gel Tablets (PH: USP 32)
  • Algeldrate (OS: Prop.INN)
  • Algeldrate (OS: USAN)
  • Algeldrato (OS: DCIT)
  • Alcid (IS)
  • Alokreen (IS)
  • Alumina hydrata (IS)
  • Aluminium hydricum (IS)
  • Aluminium hydroxydatum (IS)
  • Aluminiumhydroxid, hydratisiert (IS)
  • Aluminiumhydroxid, kolloidal (IS)
  • Aluminiumhydroxidhydrat (IS)
  • Aluminiumorthohydroxid (IS)
  • Gastralun (IS)
  • Hydrargillit (IS)
  • Tonerdehydrat (IS)
  • Trioxo-aluminium(III)-säure (IS)
  • UNII-03J11K103C (IS)
  • W 4600 (IS)
  • Aluminium Hydroxide for Adsorption Hydrated (PH: BP 2010)

Brand Names

  • Aciban (Aluminium Hydroxide and Magnesium Trisilicate)
    Be-Tabs Pharmaceuticals, South Africa


  • Acidless (Aluminium Hydroxide and Magnesium Hydroxide)
    Nakakita Yakuhin, Japan


  • Actal
    Valeant, Indonesia


  • Aflomag (Aluminium Hydroxide and Magnesium Hydroxide)
    Aflofarm, Poland


  • Airtab (Aluminium Hydroxide and Magnesium Trisilicate)
    Millimed, Thailand


  • Aisflat (Aluminium Hydroxide and Magnesium Hydroxide)
    Choseido Pharmaceutical, Japan


  • Algermin (Aluminium Hydroxide and Dicycloverine)
    Towa Yakuhin, Japan


  • Almag (Aluminium Hydroxide and Magnesium)
    B L Hua, Thailand


  • Alucol (Aluminium Hydroxide and Magnesium Hydroxide)
    Melisana, Switzerland; Sanova, Austria


  • Alum Milk (Aluminium Hydroxide and Magnesium)
    Sanofi-Aventis, Thailand


  • Alumag (Aluminium Hydroxide and Magnesium Hydroxide)
    Polfa Grodzisk, Poland


  • Alumigel
    Chugai, Japan; Sumio Yakuhin, Japan


  • Alusal
    Polfa Grodzisk, Poland


  • Alutop (Aluminium Hydroxide and Magnesium)
    General Drugs House, Thailand


  • Anacid (Aluminium Hydroxide and Magnesium Hydroxide)
    Ivax, Slovakia


  • Aquastin (Aluminium Hydroxide and Magnesium Hydroxide)
    Fuji Capseru, Japan


  • Asialum (Aluminium Hydroxide and Magnesium)
    Asian Pharmaceutical, Thailand


  • Carelox (Aluminium Hydroxide and Magnesium Hydroxide)
    Pharmacara, Oman


  • Cosaichill (Aluminium Hydroxide and Dicycloverine)
    Kyorin Rimedio, Japan


  • Crimeran (Aluminium Hydroxide and Magnesium Hydroxide)
    Takata Seiyaku, Japan


  • Daewoong Newlanta (Aluminium Hydroxide and Magnesium Hydroxide)
    Daewoong, Vietnam


  • Dicanon S (Aluminium Hydroxide and Magnesium Hydroxide)
    Nisshin Seiyaku - Yamagata, Japan


  • Dicanon (Aluminium Hydroxide and Magnesium Hydroxide)
    Nisshin Seiyaku - Yamagata, Japan


  • Digel (Aluminium Hydroxide and Magnesium Hydroxide)
    Aristopharma, Vietnam


  • Diovol (Aluminium Hydroxide and Magnesium Hydroxide)
    Church & Dwight, Canada


  • Dizicum
    Taj Pharma, India


  • Elkopas (Aluminium Hydroxide and Magnesium Carbonate)
    Demo, Greece


  • Foamcoat (Aluminium Hydroxide and Magnesium Trisilicate)
    Guardian, United States


  • Gacida (Aluminium Hydroxide and Magnesium)
    Sanofi-Aventis, Thailand


  • Gastal (Aluminium Hydroxide and Magnesium Hydroxide + Magnesium Carbonate)
    Pliva, Croatia (Hrvatska)


  • Gastro Intestinal (Aluminium Hydroxide and Alverine (veterinary use))
    Omega Pharma France, France


  • Gaviscon (Aluminium Hydroxide and Alginic Acid)
    Nordic Drugs, Norway


  • Gaviscon (Aluminium Hydroxide and Magnesium Trisilicate)
    Sanofi-Aventis, United States


  • Genaton (Aluminium Hydroxide and Magnesium Trisilicate)
    Teva USA, United States


  • Hairiesu (Aluminium Hydroxide and Magnesium Hydroxide)
    Isei, Japan


  • Hoemigel
    Mylan Pharmaceutical, Japan


  • Hydro Gel
    Iwaki Seiyaku, Japan


  • Hydroxydes Aluminium/Magnésium Sandoz Conseil (Aluminium Hydroxide and Magnesium Hydroxide)
    Sandoz, France


  • Kolantyl (Aluminium Hydroxide and Dicycloverine)
    Shionogi Seiyaku, Japan


  • Lenicet (Aluminium Hydroxide and Algeldrate)
    Athenstaedt, Germany


  • Link
    Actavis, Sweden


  • Link (Aluminium Hydroxide and Magnesium Carbonate)
    Actavis, Denmark; Actavis, Norway


  • Maalox Plus (Aluminium Hydroxide and Magnesium Hydroxide)
    Novum, Netherlands


  • Maalox (Aluminium Hydroxide and Magnesium Hydroxide)
    Sanofi Aventis, Japan; Sanofi-aventis, Greece; Sanofi-aventis, Italy; Sanofi-aventis, Vietnam; Novum, Netherlands; Sanofi-Aventis, Oman; Sanofi-Aventis, Slovakia


  • Maalox maux d'estomac (Aluminium Hydroxide and Magnesium Hydroxide)
    Sanofi-Aventis, France


  • Maaredge (Aluminium Hydroxide and Magnesium Hydroxide)
    Towa Yakuhin, Japan


  • Macmet (Aluminium Hydroxide and Magnesium Hydroxide)
    Sawai Seiyaku, Japan


  • Magtect (Aluminium Hydroxide and Magnesium Hydroxide)
    Teikoku Medix, Japan


  • Magtect U (Aluminium Hydroxide and Magnesium Hydroxide)
    Teikoku Medix, Japan


  • Malfa (Aluminium Hydroxide and Magnesium Hydroxide)
    Toyo Seiyaku KaseiOriental, Japan


  • Malugel (Aluminium Hydroxide and Magnesium Trisilicate)
    Hikma, Oman


  • Marperis (Aluminium Hydroxide and Magnesium Hydroxide)
    Sandoz, Japan


  • Medacid (Aluminium Hydroxide and Magnesium Hydroxide)
    Medpharma, Oman


  • Moxal (Aluminium Hydroxide and Magnesium Hydroxide)
    Julphar, Oman


  • Mucogel (Aluminium Hydroxide and Magnesium Hydroxide)
    Chemidex, United Kingdom; Pharmax, Oman


  • Mupax (Aluminium Hydroxide and Magnesium Hydroxide)
    Arrow, France


  • Neogelco (Aluminium Hydroxide and Magnesium Oxide)
    Kahira, Oman


  • Novagel (Aluminium Hydroxide and Magnesium Carbonate, Magnesium Hydroxide)
    Arab Pharmaceutical Manufacturing Co. LTD. - APM, Oman


  • Omacid (Aluminium Hydroxide and Magnesium hydroxide)
    National Pharmaceutical Industries Co. - NPI, Oman


  • Polmantis (Aluminium Hydroxide and Magnesium Hydroxide)
    Biogened, Poland


  • Regla-PH (Aluminium Hydroxide and Magnesium Hydroxide)
    UCB, Netherlands


  • Resporix (Aluminium Hydroxide and Dicycloverine)
    Tsuruhara Seiyaku, Japan


  • Rialox (Aluminium Hydroxide and Magnesium Hydroxide)
    Riyad Pharma, Oman


  • Ritaroks (Aluminium Hydroxide and Magnesium Hydroxide)
    Tsuruhara Seiyaku, Japan


  • Sakloft (Aluminium Hydroxide and Magnesium Hydroxide)
    Taisho Yakuhin, Japan


  • Stomafar (Aluminium Hydroxide and Magnesium Hydroxide)
    Pharmedic, Vietnam


  • Taimec (Aluminium Hydroxide and Magnesium Hydroxide)
    Taiyo Pharmaceutical, Japan


  • Takatagel
    Takata Seiyaku, Japan


  • Urusan (Aluminium Hydroxide and Magnesium Carbonate)
    Korea United Pharm, Vietnam


  • Witcop (Aluminium Hydroxide and Magnesium Hydroxide)
    Yoshindo, Japan


  • Acix
    Zentiva, Czech Republic


  • Actal
    Valeant, Sri Lanka


  • Algeldraat PCH
    Pharmachemie, Netherlands


  • Algeldraat ratiopharm
    ratiopharm, Netherlands


  • Almagel (Aluminium Hydroxide and Magnesium Hydroxide)
    Balkanpharma, Russian Federation


  • AlternaGEL
    Johnson & Johnson, United States


  • Alu-Cap
    3M, Bahrain; 3M, Israel; 3M, Kenya; 3M, Morocco; 3M, United States; 3M, Zimbabwe; IFET, Greece; Meda, United Kingdom; United Drug, Ireland


  • Aludrox
    McNeil, Ireland; Riemser, Germany; Riemser, Slovenia; Wyeth, Greece; Wyeth, India


  • Alugel
    Chefaro, Spain


  • Alumag (Aluminium Hydroxide and Aluminium Hydroxide)
    Beacons, Singapore; Teva, Israel


  • Aluminio Hidroxido L.CH
    Chile, Chile


  • Aluminio Hidroxido S.O.
    Pasteur, Chile


  • Alu-Tab
    3M, Philippines; Douglas, New Zealand; iNova, Singapore; iNova Pharmaceuticals, Australia


  • Amphojel
    Aspen Pharmacare Consumer, South Africa; Wyeth, United States


  • Antagel Katwijk (Aluminium Hydroxide and Magnesium Hydroxide)
    Apotex Europe, Netherlands


  • Antagel Kring (Aluminium Hydroxide and Magnesium Hydroxide)
    Kring, Netherlands


  • Antagel PCH (Aluminium Hydroxide and Magnesium Hydroxide)
    Pharmachemie, Netherlands


  • Antagel Ratiopharm (Aluminium Hydroxide and Magnesium Hydroxide)
    ratiopharm, Netherlands


  • Antagel Sandoz (Aluminium Hydroxide and Magnesium Hydroxide)
    Sandoz, Netherlands


  • Anti-Phosphat Gry
    Brady, Austria


  • Antiphosphat
    Teva-Gry, Germany


  • Diovol
    Wallace, India


  • Hidroxido de Aluminio
    Bestpharma, Chile; Mintlab, Chile


  • Kestomatine (Aluminium Hydroxide and Simeticone)
    Sanofi-Aventis, Belgium


  • Lenicet (Aluminium Hydroxide and Aluminium Hydroxide)
    Athenstaedt, Germany


  • Maalox
    Aventis, Ireland; Gerot, Austria; Sanofi-Aventis, Georgia


  • Maalox (Aluminium Hydroxide and Magnesium Hydroxide)
    Sanofi-Aventis, Belgium; Sanofi-Aventis, Peru; Winthrop, Germany; Winthrop, South Africa


  • Maaloxan (Aluminium Hydroxide and Magnesium Hydroxide)
    Winthrop, Germany


  • Magal II (Aluminium Hydroxide and Magnesium Hydroxide)
    Hersil, Peru


  • Maglid (Aluminium Hydroxide and Magnesium Hydroxide)
    Melisana, Belgium; Melisana, Luxembourg


  • Mayogel (Aluminium Hydroxide and Magnesium Oxide)
    Adcock Ingram Pharmaceuticals, South Africa


  • Novaluzid (Aluminium Hydroxide and Magnesium Oxide)
    BioPhausia, Denmark; BioPhausia, Norway


  • Pepsamar
    Angelini, Portugal; Gador, Argentina; Sanofi-Aventis, Colombia; Sanofi-Aventis S.A., Spain


  • Progastrit (Aluminium Hydroxide and Magnesium Hydroxide)
    Hexal, Germany


  • Rocgel
    Tonipharm, Burkina Faso; Tonipharm, Benin; Tonipharm, Central African Republic; Tonipharm, Congo; Tonipharm, Cote D'ivoire; Tonipharm, Cameroon; Tonipharm, Algeria; Tonipharm, Gabon; Tonipharm, Mali; Tonipharm, Mauritania; Tonipharm, Niger; Tonipharm, Senegal; Tonipharm, Chad; Tonipharm, Togo

International Drug Name Search

Glossary

DCITDenominazione Comune Italiana
ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
Ph. Int.Pharmacopoea Internationalis
Prop.INNProposed International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.
Posted by at No comments:
Labels:

Thursday, 10 November 2011

Clinagel




Clinagel may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Clinagel



Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Clinagel in the following countries:


  • United Kingdom

International Drug Name Search

Posted by at No comments:
Labels:

Wednesday, 9 November 2011

Sinlestal




Sinlestal may be available in the countries listed below.


Ingredient matches for Sinlestal



Probucol

Probucol is reported as an ingredient of Sinlestal in the following countries:


  • Japan

International Drug Name Search

Posted by at No comments:
Labels:

Tuesday, 8 November 2011

Eritax




Eritax may be available in the countries listed below.


Ingredient matches for Eritax



Erythromycin

Erythromycin is reported as an ingredient of Eritax in the following countries:


  • Brazil

International Drug Name Search

Posted by at No comments:
Labels:

Sunday, 6 November 2011

Uriconorm




Uriconorm may be available in the countries listed below.


Ingredient matches for Uriconorm



Allopurinol

Allopurinol is reported as an ingredient of Uriconorm in the following countries:


  • Switzerland

International Drug Name Search

Posted by at No comments:
Labels:

Thursday, 3 November 2011

Magnesium Orotate




ATC (Anatomical Therapeutic Chemical Classification)

A12CC09

CAS registry number (Chemical Abstracts Service)

0027067-77-2

Chemical Formula

C10-H6-Mg-N4-O8

Molecular Weight

334

Therapeutic Category

Mineral supplement

Chemical Name

magnesium 2,6-dioxo-3H-pyrimidine-4-carboxylate (IUPAC)

Foreign Names

  • Magnesiumorotat (German)
  • Magnésium orotate (French)
  • Orotato de magnesio (Spanish)

Generic Names

  • Orotic acid, magnesium salt (IS)
  • Orotsäure, Magnesiumsalz (IS)
  • Hippocras (IS)
  • Magnesiumorotat-2-Wasser (IS)
  • Orotsäure, Magnesiumsalz-2-Wasser (IS)

Brand Names

  • Burgerstein Magnesiumorotat
    Antistress, Switzerland


  • Magnerot
    Mauermann, Czech Republic; Mauermann, Bulgaria; Worwag, Slovakia; Wörwag Pharma, Germany; Wörwag Pharma, Georgia; Wörwag Pharma, Hungary; Wörwag Pharma, Lithuania; Wörwag Pharma, Latvia; Wörwag Pharma, Romania


  • Magnesorot
    Wörwag Pharma, Germany


  • Power Orot
    Wörwag Pharma, Germany

International Drug Name Search

Glossary

IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym

Click for further information on drug naming conventions and International Nonproprietary Names.
Posted by at No comments:
Labels:

Tuesday, 1 November 2011

Fluoxetine PCH




Fluoxetine PCH may be available in the countries listed below.


Ingredient matches for Fluoxetine PCH



Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Fluoxetine PCH in the following countries:


  • Netherlands

International Drug Name Search

Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)